Beacon Pharmaceuticals PLC (DSE: BEACONPHAR)

Market Cap	31.65B
Revenue (ttm)	9.89B
Net Income (ttm)	465.98M
Shares Out	231.00M
EPS (ttm)	2.02
PE Ratio	67.91
Forward PE	n/a
Dividend	1.60 (1.17%)
Ex-Dividend Date	n/a

Volume	413,559
Open	112.50
Previous Close	113.90
Day's Range	112.50 - 125.20
52-Week Range	111.10 - 288.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, chronic care, and biotech products. It also provides various therapeutic products that include anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, anti-histamine, analgesics, and NSAIDS, as...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 3,872
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2023, Beacon Pharmaceuticals's revenue was 8.51 billion, an increase of 6.07% compared to the previous year's 8.02 billion. Earnings were 509.84 million, a decrease of -45.47%.